AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35793178
Drug: Pulsed Radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Radiofrequency (PRF) plus Dexamethasone (5 mg in 1 mL)
Trial: 35793178
Drug: Pulsed Radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Radiofrequency (PRF) plus Normal Saline (1 mL)
Trial: 34216862
Drug: Hydromorphone (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (32 mg total IV over 270 min)
Trial: 35194646
Drug: Manual physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual physical therapy
Trial: 32627271
Drug: liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide 1.8 mg daily
Trial: 35416190
Drug: HCA group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCA group (calorie-restricted diet -700 kcal d-1 + HCA tablets)
Trial: 34749822
Drug: High-intensity interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity interval training (HIIT) intervention, 12 weeks, bicycle-based, delivered twice weekly in a face-to-face, one-to-one setting.
Trial: 34756178
Drug: IL-6 blockade
RxNorm normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-6 blockade (siltuximab 11 mg/kg or tocilizumab 8 mg/kg intravenously)
Trial: 36387033
Drug: Bright white
RxNorm normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright white light therapy (n = 13)
Trial: 33617679
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg, twice daily)
Trial: 36316861
Drug: Xuefu Zhuyu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuefu Zhuyu Granules mimic (placebo) combined with Western medicine
Trial: 33191263
Drug: Sarilumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab (200 mg and 400 mg) plus best available therapy (BAT)
Trial: 32404035
Drug: Dabigatran 110
RxNorm normalized name: dabigatran 110 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 110 mg or 150 mg twice daily
Trial: 39185955
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg once daily
Trial: 35379306
Drug: Standardized Brazilian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized Brazilian green propolis extract (900 mg/day) for 10 days
Trial: 34133205
Drug: Standard-dose gadoterate
RxNorm normalized name: GADOTERATE
DrugBank: Gadoteric acid (DB09132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose gadoterate (0.1 mmol/kg)
Trial: 35534374
Drug: Aficamten (inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aficamten (inhibitor for hypertrophic cardiomyopathy)
Trial: 32591475
Drug: Natalizumab 300
RxNorm normalized name: natalizumab 300 MG in 15 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab 300 mg
Trial: 34418858
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (age-matched healthy elderly, no stretching treatment)
Trial: 32444619
Drug: Compassionate coach
RxNorm normalized name: coachwhip stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compassionate coach (CC) image
Trial: 34423693
Drug: Client-Centered (CC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-Centered (CC) intervention with telerehabilitation (TR) method
Trial: 38060077
Drug: Compression therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression therapy
Trial: 37707817
Drug: High-dose trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose trivalent influenza vaccine
Trial: 35331539
Drug: Moderate‐carbohydrate diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate‐carbohydrate diet with calorie‐counting method (MCD‐CC)
Trial: 33293185
Drug: Dexmedetomidine 10
RxNorm normalized name: dexmedeTOMIDine 1000 MG in 250 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 10 µg
Trial: 34101892
Drug: Rivoceranib 201
RxNorm normalized name: Rivoceranib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivoceranib 201 mg with food
Trial: 32510130
Drug: Kisspeptin-10 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kisspeptin-10 (4 µg/kg/h i.v.) without NK3Ra treatment
Trial: 38360588
Drug: Antiplatelet agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet agents
Trial: 34591356
Drug: enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 10 mg bid (n=98)
Trial: 32468672
Drug: sacubitril/valsartan 97/103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan 97/103 mg bid
Trial: 33033091
Drug: Patient-controlled regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled regional analgesia (PCRA) - ultrasound-guided subgluteal sciatic catheterisation, continuous infusion of 0.2% ropivacaine (15 mL loading dose, 8 mL/hour background, 6 mL patient-controlled bolus)
Trial: 33033091
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PCIA) - morphine in boluses of 1 mg as needed, background infusion at 1 mg/hour
Trial: 36364907
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Irvingia gabonensis (IG) extract
Trial: 33462622
Drug: Bloodletting (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bloodletting (3 scheduled bloodlettings after a 3-month run-in period with 35 μg ethinylestradiol plus 2 mg cyproterone acetate)
Trial: 33462622
Drug: Observation (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (after a 3-month run-in period with 35 μg ethinylestradiol plus 2 mg cyproterone acetate)
Trial: 33990812
Drug: Vitrification solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitrification solutions with sucrose (VS1)
Trial: 33990812
Drug: Vitrification solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitrification solutions without sucrose (VS2 and VS4)
Trial: 33990812
Drug: Warming solution
RxNorm normalized name: CVS Flu & Sore Throat Warming Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming solution containing trehalose
Trial: 33990812
Drug: Warming solution
RxNorm normalized name: CVS Flu & Sore Throat Warming Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming solution containing sucrose
Trial: 34970487
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment
Trial: 32787783
Drug: Prophylactic methoxamine
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic methoxamine infusion at 1 μg/kg/min (Group M1)
Trial: 32787783
Drug: Prophylactic methoxamine
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic methoxamine infusion at 2 μg/kg/min (Group M2)
Trial: 32787783
Drug: Prophylactic methoxamine
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic methoxamine infusion at 3 μg/kg/min (Group M3)
Trial: 32787783
Drug: Prophylactic methoxamine
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic methoxamine infusion at 4 μg/kg/min (Group M4)
Trial: 32787783
Drug: Prophylactic methoxamine
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic methoxamine infusion (all groups)
Trial: 32664033
Drug: Drug expectation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug expectation group (expectation to receive a fast-operating antidepressant)
Trial: 32918892
Drug: All pooled
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All pooled treatment groups
Trial: 34816288
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (late-PN)
Trial: 616063481
Drug: V+CEF (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V+CEF (3 cycles of weekly vinorelbine followed by 3 cycles of CEF)
Trial: 35581629
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/day for 6 weeks
Trial: 33210997
Drug: Trial preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial preparation (sildenafil tablet 20 mg)
Trial: 33210997
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation (sildenafil tablet 20 mg)
Trial: 32185595
Drug: CFα late‐start:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFα late‐start: CFα on day 4 + GnRH antagonist from day 8 + recFSH from day 11 (when needed)
Trial: 34725792
Drug: PIEB delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIEB delivered at 125 mL·hr-1 (G125)
Trial: 34725792
Drug: PIEB delivered
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIEB delivered at 250 mL·hr-1 (G250)
Trial: 32601120
Drug: Bilateral STN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral STN deep brain stimulation (DBS) plus optimal drug therapy (ODT)
Trial: 35569129
Drug: Dupilumab (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (600 mg induction dose, followed by 300 mg every 2 weeks for patients ≥60 kg; 400 mg loading dose followed by 200 mg every 2 weeks for patients <60 kg)
Trial: 38588929
Drug: Empagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10 mg daily)
Trial: 33273258
Drug: Prucalopride (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride (2 mg/d before breakfast over 32 weeks)
Trial: 33716173
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise (EX) plus 1% testosterone topical gel
Trial: 33716173
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise (EX) plus placebo gel
Trial: 33905751
Drug: Once-weekly exenatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly exenatide (EQW)
Trial: 33557254
Drug: Dog-assisted therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dog-assisted therapy
Trial: 34432394
Drug: Reciprocating automated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reciprocating automated preparation system (WaveOne®) (n = 53)
Trial: 34432394
Drug: Rotary preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotary preparation system (ProTaper Next®) (n = 52)
Trial: 33866248
Drug: CFI-400945 (PLK4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFI-400945 (PLK4 inhibitor) combined with radiation therapy
Trial: 33866248
Drug: Control or
RxNorm normalized name: Dayquil Mucus Control Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control or single-agent treatment
Trial: 32672635
Drug: Intra-Tenon injection
RxNorm normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-Tenon injection of 0.1 ml of 0.01% MMC (TI group)
Trial: 35451013
Drug: 1, 2,
RxNorm normalized name: Pneumococcal 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2, 4, 8 or 12 µg CG beta added to follitropin delta
Trial: 33106225
Drug: Very early
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very early ECMO plus standard pharmacotherapy
Trial: 36000541
Drug: Zanidatamab plus
RxNorm normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanidatamab plus chemotherapy
Trial: 32536177
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600 mg every 12 hours for 10 days
Trial: 33222860
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (tulathromycin, 2.5 mg/kg subcutaneous)
Trial: 35993223
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal block (ACB) with 15 mL mixture of ropivacaine 0.2% with isotonic saline and steroids on post-operative day 14 (POD-14)
Trial: 34810130
Drug: Concurrent chemotherapy-immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy-immunotherapy with pembrolizumab and multisite radiotherapy
Trial: 34810130
Drug: Concurrent chemotherapy-immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy-immunotherapy with pembrolizumab
Trial: 36208670
Drug: 10 mM
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mM Ascorbate (non-specific ROS inhibitor)
Trial: 36208670
Drug: Ascorbate+L-NAME
RxNorm normalized name: L-Ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbate+L-NAME
Trial: 33723919
Drug: CBD 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 0.5 mg/kg
Trial: 33723919
Drug: CBD 2
RxNorm normalized name: MENTHOL 0.06 g in 1 g TOPICAL GEL [SOMBRA PLUS CBD 2000MG COOL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 2 mg/kg
Trial: 34223660
Drug: CBD (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (all doses)
Trial: 35245416
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy
Trial: 33635382
Drug: Flumazenil infusion
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil infusion
Trial: 32887793
Drug: DHA +
RxNorm normalized name: PNV-DHA + Docusate Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA + AA supplementation (200 mg DHA + 200 mg AA daily for 180 days)
Trial: 34269067
Drug: Tislelizumab plus
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab plus concurrent chemoradiotherapy
Trial: 34269067
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus concurrent chemoradiotherapy
Trial: 33190032
Drug: Almorexant 200
RxNorm normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Almorexant 200 mg
Trial: 32384291
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg) + Magnesium sulfate (3g)
Trial: 36084236
Drug: Levagen+ (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levagen+ (600 mg twice daily for 4 weeks)
Trial: 39318719
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 4 weeks)
Trial: 34042543
Drug: Conventional Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Therapy (Control)
Trial: 35273049
Drug: High-dose pyrazinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pyrazinamide (40 mg/kg) and rifampicin (35 mg/kg) along with standard doses of isoniazid and ethambutol
Trial: 35273049
Drug: Standardised TB
RxNorm normalized name: TB-402
DrugBank: TB-402 (DB06050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised TB treatment (6-month regimen)
Trial: 35273049
Drug: High-dose pyrazinamide-rifampicin
RxNorm normalized name: rifampicin, pyrazinamide and isoniazid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pyrazinamide-rifampicin regimen
Trial: 34288106
Drug: Bipolar radiofrequency
RxNorm normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bipolar radiofrequency treatment
Trial: 34288106
Drug: Monopolar radiofrequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monopolar radiofrequency treatment
Trial: 37231386
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation therapy (SMT)
Trial: 33184083
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) 400 mg/100 mg two times per day for 5 days
Trial: 33184083
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (no treatment)
Trial: 33809162
Drug: Sodium hypochlorite
RxNorm normalized name: Sodium hypochlorite
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium hypochlorite (NaOCl) treatment for 30 minutes
Trial: 33740465
Drug: CC-11050 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-11050 (200 mg twice daily, taken with food; day 1-112)
Trial: 33740465
Drug: Everolimus (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (0.5 mg/day; day 1-112)
Trial: 33740465
Drug: Auranofin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auranofin (3 mg/day for seven doses, then 6 mg/day; day 1-112)
Trial: 34302325
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL of plain milk (Control)
Trial: 34302325
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation of 200 mL milk fortified with 240 IU of ergocalciferol (vitamin D2)
Trial: 33030983
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g leucine (LEU) daily
Trial: 39320582
Drug: Tofacitinib 2
RxNorm normalized name: tofacitinib 22 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 2 mg BID
Trial: 36471444
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine patch (LP5)
Trial: 35713342
Drug: Add-on treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on treatment
Trial: 35713342
Drug: Monotherapy treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy treatment
Trial: 35999617
Drug: Azithromycin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (20 mg/kg for 3 days; 10 mg/kg for 7 days)
Trial: 35689137
Drug: App-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based cognitive behavioral therapy (CBT) program
Trial: 32660977
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixekizumab (IXE) monotherapy
Trial: 35932230
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g intravenous amoxicillin‐clavulanic acid after the induction of anaesthesia
Trial: 36458661
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of trimetazidine dihydrochloride (35 mg)
Trial: 36458661
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of trimetazidine dihydrochloride (35 mg)
Trial: 35222091
Drug: Sacubitril valsartan
RxNorm normalized name: sacubitril / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril valsartan (SV) treatment administered ultra-early (2 hours post-PCI)
Trial: 35222091
Drug: Sacubitril valsartan
RxNorm normalized name: sacubitril / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril valsartan (SV) treatment administered after 3–7 days post-PCI
Trial: 35222091
Drug: Sacubitril valsartan
RxNorm normalized name: sacubitril / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril valsartan (SV) treatment
Trial: 35401970
Drug: Iron supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplements or iron-containing multiple micronutrient powders (MNPs)
Trial: 32696982
Drug: Patch testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch testing in pediatric patients
Trial: 32696982
Drug: Patch testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch testing in adult patients (control group)
Trial: 33731544
Drug: sacubitril/valsartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan 200 mg bid
Trial: 35988178
Drug: Aminophylline treatment
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline treatment
Trial: 32585392
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefenamic acid (250 mg)
Trial: 36096984
Drug: Tivozanib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib 1.5 mg orally once daily in 4-week cycles
Trial: 33296519
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (16-40 IU/day, twice daily)
Trial: 33208878
Drug: Esomeprazole (Eso)
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole (Eso) 40 mg/day